National Cancer Institute's cancer disparities research partnership program: Experience and lessons learned

Rosemary S L Wong, Bhadrasain Vikram, Frank S. Govern, Daniel G. Petereit, Patrick D. Maguire, Maggie R. Clarkson, Dwight E. Heron, C. Norman Coleman

Research output: Contribution to journalArticle

Abstract

Purpose: To increase access of underserved/health disparities communities to National Cancer Institute (NCI) clinical trials, the Radiation Research Program piloted a unique model - the Cancer Disparities Research Partnership (CDRP) program. CDRP targeted community hospitals with a limited past NCI funding history and provided funding to establish the infrastructure for their clinical research program. Methods: Initially, 5-year planning phase funding was awarded to six CDRP institutions through a cooperative agreement (U56). Five were subsequently eligible to compete for 5-year implementation phase (U54) funding and three received a second award. Additionally, the NCI Center to Reduce Cancer Health Disparities supported their U56 patient navigation programs. Results: Community-based hospitals with little or no clinical trials experience required at least a year to develop the infrastructure and establish community outreach/education and patient navigation programs before accrual to clinical trials could begin. Once established, CDRP sites increased their yearly patient accrual mainly to NCI-sponsored cooperative group trials (~60%) and Principal Investigator/mentor-initiated trials (~30%). The total number of patients accrued on all types of trials was 2,371, while 5,147 patients received navigation services. Conclusion: Despite a historical gap in participation in clinical cancer research, underserved communities are willing/eager to participate. Since a limited number of cooperative group trials address locally advanced diseases seen in health disparities populations; this shortcoming needs to be rectified. Sustainability for these programs remains a challenge. Addressing these gaps through research and public health mechanisms may have an important impact on their health, scientific progress, and efforts to increase diversity in NCI clinical trials.

Original languageEnglish (US)
Article number303
JournalFrontiers in Oncology
Volume4
Issue numberNOV
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

National Cancer Institute (U.S.)
Patient Navigation
Research
Neoplasms
Clinical Trials
Community Hospital
Health
Community-Institutional Relations
Mentors
Program Evaluation
Patient Education
Public Health
History
Research Personnel
Radiation

Keywords

  • Access to clinical trials
  • Cancer disparities
  • Clinical research
  • Patient accrual
  • Underserved populations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Wong, R. S. L., Vikram, B., Govern, F. S., Petereit, D. G., Maguire, P. D., Clarkson, M. R., ... Coleman, C. N. (2014). National Cancer Institute's cancer disparities research partnership program: Experience and lessons learned. Frontiers in Oncology, 4(NOV), [303]. https://doi.org/10.3389/fonc.2014.00303

National Cancer Institute's cancer disparities research partnership program : Experience and lessons learned. / Wong, Rosemary S L; Vikram, Bhadrasain; Govern, Frank S.; Petereit, Daniel G.; Maguire, Patrick D.; Clarkson, Maggie R.; Heron, Dwight E.; Coleman, C. Norman.

In: Frontiers in Oncology, Vol. 4, No. NOV, 303, 2014.

Research output: Contribution to journalArticle

Wong, RSL, Vikram, B, Govern, FS, Petereit, DG, Maguire, PD, Clarkson, MR, Heron, DE & Coleman, CN 2014, 'National Cancer Institute's cancer disparities research partnership program: Experience and lessons learned', Frontiers in Oncology, vol. 4, no. NOV, 303. https://doi.org/10.3389/fonc.2014.00303
Wong, Rosemary S L ; Vikram, Bhadrasain ; Govern, Frank S. ; Petereit, Daniel G. ; Maguire, Patrick D. ; Clarkson, Maggie R. ; Heron, Dwight E. ; Coleman, C. Norman. / National Cancer Institute's cancer disparities research partnership program : Experience and lessons learned. In: Frontiers in Oncology. 2014 ; Vol. 4, No. NOV.
@article{9c1c69d082d34b049d14b48ea9414359,
title = "National Cancer Institute's cancer disparities research partnership program: Experience and lessons learned",
abstract = "Purpose: To increase access of underserved/health disparities communities to National Cancer Institute (NCI) clinical trials, the Radiation Research Program piloted a unique model - the Cancer Disparities Research Partnership (CDRP) program. CDRP targeted community hospitals with a limited past NCI funding history and provided funding to establish the infrastructure for their clinical research program. Methods: Initially, 5-year planning phase funding was awarded to six CDRP institutions through a cooperative agreement (U56). Five were subsequently eligible to compete for 5-year implementation phase (U54) funding and three received a second award. Additionally, the NCI Center to Reduce Cancer Health Disparities supported their U56 patient navigation programs. Results: Community-based hospitals with little or no clinical trials experience required at least a year to develop the infrastructure and establish community outreach/education and patient navigation programs before accrual to clinical trials could begin. Once established, CDRP sites increased their yearly patient accrual mainly to NCI-sponsored cooperative group trials (~60{\%}) and Principal Investigator/mentor-initiated trials (~30{\%}). The total number of patients accrued on all types of trials was 2,371, while 5,147 patients received navigation services. Conclusion: Despite a historical gap in participation in clinical cancer research, underserved communities are willing/eager to participate. Since a limited number of cooperative group trials address locally advanced diseases seen in health disparities populations; this shortcoming needs to be rectified. Sustainability for these programs remains a challenge. Addressing these gaps through research and public health mechanisms may have an important impact on their health, scientific progress, and efforts to increase diversity in NCI clinical trials.",
keywords = "Access to clinical trials, Cancer disparities, Clinical research, Patient accrual, Underserved populations",
author = "Wong, {Rosemary S L} and Bhadrasain Vikram and Govern, {Frank S.} and Petereit, {Daniel G.} and Maguire, {Patrick D.} and Clarkson, {Maggie R.} and Heron, {Dwight E.} and Coleman, {C. Norman}",
year = "2014",
doi = "10.3389/fonc.2014.00303",
language = "English (US)",
volume = "4",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "NOV",

}

TY - JOUR

T1 - National Cancer Institute's cancer disparities research partnership program

T2 - Experience and lessons learned

AU - Wong, Rosemary S L

AU - Vikram, Bhadrasain

AU - Govern, Frank S.

AU - Petereit, Daniel G.

AU - Maguire, Patrick D.

AU - Clarkson, Maggie R.

AU - Heron, Dwight E.

AU - Coleman, C. Norman

PY - 2014

Y1 - 2014

N2 - Purpose: To increase access of underserved/health disparities communities to National Cancer Institute (NCI) clinical trials, the Radiation Research Program piloted a unique model - the Cancer Disparities Research Partnership (CDRP) program. CDRP targeted community hospitals with a limited past NCI funding history and provided funding to establish the infrastructure for their clinical research program. Methods: Initially, 5-year planning phase funding was awarded to six CDRP institutions through a cooperative agreement (U56). Five were subsequently eligible to compete for 5-year implementation phase (U54) funding and three received a second award. Additionally, the NCI Center to Reduce Cancer Health Disparities supported their U56 patient navigation programs. Results: Community-based hospitals with little or no clinical trials experience required at least a year to develop the infrastructure and establish community outreach/education and patient navigation programs before accrual to clinical trials could begin. Once established, CDRP sites increased their yearly patient accrual mainly to NCI-sponsored cooperative group trials (~60%) and Principal Investigator/mentor-initiated trials (~30%). The total number of patients accrued on all types of trials was 2,371, while 5,147 patients received navigation services. Conclusion: Despite a historical gap in participation in clinical cancer research, underserved communities are willing/eager to participate. Since a limited number of cooperative group trials address locally advanced diseases seen in health disparities populations; this shortcoming needs to be rectified. Sustainability for these programs remains a challenge. Addressing these gaps through research and public health mechanisms may have an important impact on their health, scientific progress, and efforts to increase diversity in NCI clinical trials.

AB - Purpose: To increase access of underserved/health disparities communities to National Cancer Institute (NCI) clinical trials, the Radiation Research Program piloted a unique model - the Cancer Disparities Research Partnership (CDRP) program. CDRP targeted community hospitals with a limited past NCI funding history and provided funding to establish the infrastructure for their clinical research program. Methods: Initially, 5-year planning phase funding was awarded to six CDRP institutions through a cooperative agreement (U56). Five were subsequently eligible to compete for 5-year implementation phase (U54) funding and three received a second award. Additionally, the NCI Center to Reduce Cancer Health Disparities supported their U56 patient navigation programs. Results: Community-based hospitals with little or no clinical trials experience required at least a year to develop the infrastructure and establish community outreach/education and patient navigation programs before accrual to clinical trials could begin. Once established, CDRP sites increased their yearly patient accrual mainly to NCI-sponsored cooperative group trials (~60%) and Principal Investigator/mentor-initiated trials (~30%). The total number of patients accrued on all types of trials was 2,371, while 5,147 patients received navigation services. Conclusion: Despite a historical gap in participation in clinical cancer research, underserved communities are willing/eager to participate. Since a limited number of cooperative group trials address locally advanced diseases seen in health disparities populations; this shortcoming needs to be rectified. Sustainability for these programs remains a challenge. Addressing these gaps through research and public health mechanisms may have an important impact on their health, scientific progress, and efforts to increase diversity in NCI clinical trials.

KW - Access to clinical trials

KW - Cancer disparities

KW - Clinical research

KW - Patient accrual

KW - Underserved populations

UR - http://www.scopus.com/inward/record.url?scp=84915803832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84915803832&partnerID=8YFLogxK

U2 - 10.3389/fonc.2014.00303

DO - 10.3389/fonc.2014.00303

M3 - Article

C2 - 25405101

AN - SCOPUS:84915803832

VL - 4

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - NOV

M1 - 303

ER -